SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 123 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85,415,873 | -18.2% | 5,882,636 | +17.9% | 0.00% | -33.3% |
| Q2 2023 | $104,461,295 | +0.9% | 4,990,984 | +1.8% | 0.00% | 0.0% |
| Q1 2023 | $103,505,761 | -6.5% | 4,900,841 | +12.6% | 0.00% | 0.0% |
| Q4 2022 | $110,759,215 | +11.3% | 4,352,032 | +5.1% | 0.00% | 0.0% |
| Q3 2022 | $99,476,000 | +36.2% | 4,139,617 | +9.1% | 0.00% | +50.0% |
| Q2 2022 | $73,032,000 | +10.6% | 3,795,909 | -0.1% | 0.00% | 0.0% |
| Q1 2022 | $66,011,000 | -18.3% | 3,798,150 | +2.9% | 0.00% | 0.0% |
| Q4 2021 | $80,771,000 | +19.9% | 3,689,894 | +4.6% | 0.00% | 0.0% |
| Q3 2021 | $67,389,000 | +11.5% | 3,526,298 | +0.2% | 0.00% | 0.0% |
| Q2 2021 | $60,436,000 | +0.9% | 3,519,894 | +31.5% | 0.00% | 0.0% |
| Q1 2021 | $59,869,000 | +16.0% | 2,677,505 | +15.4% | 0.00% | 0.0% |
| Q4 2020 | $51,607,000 | +86.3% | 2,320,406 | +23.7% | 0.00% | +100.0% |
| Q3 2020 | $27,695,000 | -12.8% | 1,876,358 | -12.4% | 0.00% | 0.0% |
| Q2 2020 | $31,747,000 | +20.2% | 2,142,069 | -11.1% | 0.00% | 0.0% |
| Q1 2020 | $26,418,000 | +75.5% | 2,408,235 | +40.5% | 0.00% | 0.0% |
| Q4 2019 | $15,054,000 | +17.6% | 1,714,481 | +0.1% | 0.00% | 0.0% |
| Q3 2019 | $12,799,000 | -18.2% | 1,713,304 | +1.9% | 0.00% | 0.0% |
| Q2 2019 | $15,655,000 | +99.1% | 1,681,507 | +12.3% | 0.00% | – |
| Q1 2019 | $7,863,000 | +12.2% | 1,497,635 | -4.9% | 0.00% | – |
| Q4 2018 | $7,010,000 | -50.6% | 1,574,931 | -10.4% | 0.00% | -100.0% |
| Q3 2018 | $14,202,000 | +21.1% | 1,757,844 | +5.2% | 0.00% | 0.0% |
| Q2 2018 | $11,729,000 | -35.4% | 1,670,816 | +30.9% | 0.00% | 0.0% |
| Q1 2018 | $18,168,000 | +80.4% | 1,276,671 | +11.0% | 0.00% | – |
| Q4 2017 | $10,072,000 | -55.9% | 1,149,730 | -41.1% | 0.00% | -100.0% |
| Q3 2017 | $22,837,000 | -13.5% | 1,951,890 | +3.3% | 0.00% | 0.0% |
| Q2 2017 | $26,390,000 | +30.9% | 1,889,109 | +28.5% | 0.00% | 0.0% |
| Q1 2017 | $20,167,000 | +6163.0% | 1,469,908 | +3177.3% | 0.00% | – |
| Q4 2016 | $322,000 | -52.6% | 44,851 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $680,000 | +53.8% | 44,851 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $442,000 | -25.6% | 44,851 | +0.6% | 0.00% | 0.0% |
| Q1 2016 | $594,000 | – | 44,595 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |